Search hospitals > Mississippi > Jackson
University Of Mississippi Medical Center
Claim this profileJackson, Mississippi 39216
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Brain Tumor
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
1030 reported clinical trials
45 medical researchers
Summary
University Of Mississippi Medical Center is a medical facility located in Jackson, Mississippi. This center is recognized for care of Cancer, Leukemia, Brain Tumor, Lung Cancer, Ovarian Cancer and other specialties. University Of Mississippi Medical Center is involved with conducting 1,030 clinical trials across 1,191 conditions. There are 45 research doctors associated with this hospital, such as Anderson (Andy) B. Collier, Betty L. Herrington, John C. Henegan, and Dennis P. Morgan.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Leukemia
Global LeaderNTRK1 positive
NTRK positive
Philadelphia chromosome positive
Top PIs
Anderson (Andy) B. CollierUniversity of Mississippi Medical Center8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
52 reported clinical trials
102 drugs studied
Betty L. HerringtonUniversity of Mississippi Medical Center8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
47 reported clinical trials
108 drugs studied
John C. HeneganUniversity of Mississippi Medical Center4 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
18 reported clinical trials
65 drugs studied
Dennis P. MorganUniversity of Mississippi Medical Center6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied
Clinical Trials running at University Of Mississippi Medical Center
Prostate Cancer
Lung Cancer
Brain Tumor
Heart Failure
Breast cancer
Testicular cancer
Neuroblastoma
Bladder Cancer
Cancer
Breast Cancer
Docetaxel + Hormone Therapy
for Prostate Cancer
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Recruiting2 awards Phase 35 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
Carboplatin + Cabazitaxel
for Prostate Cancer
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Of Mississippi Medical Center?
University Of Mississippi Medical Center is a medical facility located in Jackson, Mississippi. This center is recognized for care of Cancer, Leukemia, Brain Tumor, Lung Cancer, Ovarian Cancer and other specialties. University Of Mississippi Medical Center is involved with conducting 1,030 clinical trials across 1,191 conditions. There are 45 research doctors associated with this hospital, such as Anderson (Andy) B. Collier, Betty L. Herrington, John C. Henegan, and Dennis P. Morgan.
Where is University Of Mississippi Medical Center located?
The University of Mississippi Medical Center is located at 2500 N State St, Jackson, MS 39216. Access is available via the stoplight at University Drive on North State Street or by taking I-55 to the Woodrow Wilson exit (98A), following signs to the new Children's Parking Garage C.
Who should I call to ask about financial aid or insurance network?
**University Of Mississippi Medical Center (UMMC) Financial and Billing Information:**
- For financial assistance, contact Patient Financial Services at 410-821-4140 or 877-632-4909 (toll-free) to check eligibility for the UMMC Financial Assistance Program or other assistance programs.
- For insurance inquiries, reach out to the Mississippi Insurance Department via their website.
- For billing questions or concerns, contact UMMC's Central Billing Office at (601) 496-9303 or (844) 838-4871.
What insurance does University Of Mississippi Medical Center accept?
The University of Mississippi Medical Center (UMMC) accepts various insurance plans, including those from UnitedHealthcare, Blue Cross Blue Shield of Mississippi, and Humana. UMMC offers a student insurance plan through UnitedHealthcare for students with at least 6 credit hours and their dependents; international students are required to have health insurance. Additionally, UMMC has in-network agreements with Blue Cross Blue Shield for all commercial health plans and with Humana for Medicare Advantage HMO and PPO plan members.
What awards or recognition has University Of Mississippi Medical Center received?
The University of Pennsylvania has been awarded the 2022 update to the research and development section.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.